Precigen (PGEN) Expected to Announce Quarterly Earnings on Wednesday

Key Points

• Precigen is expected to report Q3 2026 results after the market closes on November 4, with analysts forecasting earnings of $0.0589 per share and revenue of $71.56 million.
• In its latest quarter, Precigen beat earnings expectations, reporting $0.05 per share versus a $0.01 loss estimate, while revenue reached $54.98 million—up more than 6,300% year over year.
• Analyst sentiment is mixed but leans positive: the stock has a “Moderate Buy” consensus rating and an average price target of $13.67, compared with a recent share price of $6.64. Insiders have sold more than 301,000 shares worth approximately $2.2 million over the past 90 days.

Precigen (NASDAQ:PGEN - Get Free Report) is expected to issue its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect the company to announce earnings of $0.0589 per share and revenue of $71.56 million for the quarter. Individuals can check the company's upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 4:30 PM ET.

Precigen (NASDAQ:PGEN - Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The biotechnology company reported $0.05 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.01) by $0.06. The firm had revenue of $54.98 million during the quarter, compared to analyst estimates of $27.98 million. Precigen had a negative net margin of 183.98% and a positive return on equity of 423.75%. The company's revenue for the quarter was up 6322.7% compared to the same quarter last year. On average, analysts expect Precigen to post $0.23 EPS for the current fiscal year and $0.72 EPS for the next fiscal year.

Precigen Stock Up 9.2%

Shares of PGEN opened at $6.64 on Friday. The stock has a market cap of $2.37 billion, a price-to-earnings ratio of -6.38 and a beta of 0.92. The company has a quick ratio of 3.89, a current ratio of 4.58 and a debt-to-equity ratio of 2.15. Precigen has a 12 month low of $3.04 and a 12 month high of $8.98. The company has a 50-day moving average price of $7.23 and a two-hundred day moving average price of $5.26.

Wall Street Analyst Weigh In

PGEN has been the topic of several analyst reports. Wall Street Zen upgraded Precigen from a "hold" rating to a "strong-buy" rating in a research note on Saturday, August 8th. B. Riley Financial assumed coverage on Precigen in a research report on Friday, September 25th. They set a "buy" rating and a $12.00 target price for the company. HC Wainwright boosted their price target on Precigen from $14.00 to $18.00 and gave the company a "buy" rating in a research note on Wednesday, August 5th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Precigen in a research note on Thursday, October 15th. Finally, Zacks Research cut Precigen from a "strong-buy" rating to a "hold" rating in a research report on Monday, October 5th. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $13.67.

Insider Buying and Selling

In other Precigen news, COO Rutul R. Shah sold 15,342 shares of the firm's stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $7.50, for a total value of $115,065.00. Following the completion of the sale, the chief operating officer owned 468,865 shares in the company, valued at approximately $3,516,487.50. This trade represents a 3.17% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Jeffrey B. Kindler sold 185,000 shares of the business's stock in a transaction dated Wednesday, August 26th. The stock was sold at an average price of $7.44, for a total transaction of $1,376,400.00. Following the completion of the transaction, the director directly owned 17,100 shares of the company's stock, valued at approximately $127,224. This represents a 91.54% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 301,511 shares of company stock worth $2,195,508. 41.40% of the stock is owned by corporate insiders.

Precigen Company Profile

Precigen, Inc is a clinical-stage biotechnology company focused on developing gene and cell therapies for cancer and serious diseases. The company uses its proprietary UltraCAR-T, AdenoVerse, and other gene-engineering platforms to design potential treatments intended to improve the targeting, persistence, and manufacturing of therapeutic cells and genetic medicines.

Precigen's pipeline has included PRGN-2012, an investigational immunotherapy based on a gorilla adenovector for recurrent respiratory papillomatosis, as well as PRGN-2001, an investigational HPV-targeted immunotherapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.